Biomapas UAB
Biomapas UAB is recorded as a service provider in 11 clinical trials. Explore its recorded services, study phases and therapeutic areas, with trial-level operational learnings where available.
Clinical trial experience
Showing 11 of 11 trials · Latest update first
A Multicenter Phase 2b Randomized, Double-Masked, Placebo-Controlled Dose-Ranging Study of TOUR006 in Participants with Thyroid Eye Disease.
Sponsor Tourmaline Bio Inc.
- Start (EU)
- Latest update
- Estimated end
A randomised active-controlled trial to assess the safety and pharmacodynamics of two blinded doses of vortosiran and open-label apixaban in patients with non-valvular atrial fibrillation
Sponsor Ribocure Pharmaceuticals AB
- Start (EU)
- Not reported
- Latest update
- Estimated end
- Not reported
A Phase IIb, Monocentric, Non-Profit, Open-label Trial for the Intrathecal Administration of AAV9/AP4M1 for Hereditary Spastic Paraplegia Type 50 (SPG50)
Sponsor Azienda Socio Sanitaria Territoriale Papa Giovanni Xxiii
- Start (EU)
- Latest update
- Estimated end
- Not reported
Adaptive, Phase 2/3, Randomized, Double-Blind Trial Investigating the Efficacy and Safety of Visugromab versus Placebo in Patients with Cancer-associated Cachexia
Sponsor CatalYm GmbH
- Start (EU)
- Latest update
- Estimated end
A Phase II Randomized, Open-label, Multi-center Study of the Safety and Efficacy of IMCgp100 Compared with Investigator’s Choice in HLA-A*0201 Positive Patients with Previously Untreated Advanced Uveal Melanoma
Sponsor Immunocore Limited
- Start (EU)
- Latest update
- Estimated end
Operational learnings available2 trial-level findings · Read insights
- The study randomized 378 patients at 58 sites in 14 countries.
- Tebentafusp required at least 16 hours of inpatient monitoring after dosing on Cycle 1 Days 1, 8, and 15 because of anticipated cytokine release syndrome.
These findings describe the trial, not the service provider’s performance or responsibility.
Intrathecal Administration of MELPIDA for Hereditary Spastic Paraplegia Type 50 (SPG50): A Multicenter Phase 3, Open-Label Trial with Matched Prospective Concurrent Control Arm (CT-MEL-03)
Sponsor Elpida Therapeutics SPC
- Start (EU)
- Not reported
- Latest update
- Estimated end
A Double-Blind, Randomized, Placebo-Controlled Study to Investigate the Safety and Efficacy of Aritinercept, a Dual BAFF/APRIL Inhibitor, in Patients with Generalized Myasthenia Gravis
Sponsor Aurinia Pharmaceuticals Inc.
- Start (EU)
- Latest update
- Estimated end
A Phase 3, Multi-Center, Randomized, Single-Blind Study to Assess the Efficacy and Safety of Cefepime/Nacubactam and Aztreonam/Nacubactam Versus Best Available Therapy in Adults With Complicated Urinary Tract Infection, Acute Uncomplicated Pyelonephritis, Hospital-Acquired Bacterial Pneumonia, Ventilator-Associated Bacterial Pneumonia, and Complicated Intra-Abdominal Infection due to Carbapenem Resistant Enterobacterales (OP0595-6)
Sponsor Meiji Seika Pharma Co. Ltd.
- Start (EU)
- Latest update
- Estimated end
A Phase IIb, Non-Profit, Open-label Trial for the Intrathecal Administration of AAV9/AP4M1 for Hereditary Spastic Paraplegia Type 50 (SPG50).
Sponsor Rigshospitalet
- Start (EU)
- Not reported
- Latest update
- Estimated end
- Not reported
A Phase 3, Multi-Center, Randomized, Double-Blind Study to Evaluate the Efficacy and Safety of Cefepime/Nacubactam or Aztreonam/Nacubactam Compared to Imipenem/Cilastatin in the Treatment of Complicated Urinary Tract Infections or Acute Uncomplicated Pyelonephritis, in Adults (OP0595-5)
Sponsor Meiji Seika Pharma Co. Ltd.
- Start (EU)
- Latest update
- Estimated end
A Phase 3, Multicenter, Open-Label, Randomized Study of Nemvaleukin Alfa in Combination With Pembrolizumab Versus Investigator’s Choice Chemotherapy in Patients With Platinum-Resistant Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer (ARTISTRY-7)
Sponsor Mural Oncology Inc.
- Start (EU)
- Latest update
- Estimated end
Questions about this trial experience
What services are recorded for Biomapas UAB?
The 2026-10-09 snapshot links Biomapas UAB to 11 distinct CTIS trials. Recorded services include Regulatory services, Clinical monitoring, Safety reporting & pharmacovigilance, Investigator recruitment, among 6 recorded service labels. These are study-specific roles, not a complete or independently verified capability catalogue.
Which therapeutic areas and study phases are recorded for Biomapas UAB?
The most frequently recorded therapeutic areas are Ophthalmology, Solid Tumor Oncology, Cardiology, Endocrinology. Recorded phases include Phase 2, Phase 3. Use the filters to inspect the supporting studies; missing tags are not evidence of absent experience.
In which countries are trials linked to Biomapas UAB conducted?
The linked trials record locations in 21 countries, including Spain, France, Italy, Poland, Czechia. These are trial locations, not confirmed office locations or countries where Biomapas UAB delivered services.
What can this page tell me about Biomapas UAB's trial experience?
Browse 11 distinct trials with recorded roles, sponsor names, available study dates and links to CTIS source records. 1 trials have operational findings that can inform further due diligence. Trial counts and findings do not measure the provider’s performance or establish responsibility for study outcomes.
About this data & company names
One current approved profile per CTIS trial. Services reflect recorded roles, not a complete capability catalogue or a performance ranking. Missing tags mean the information was not recorded. Country tags describe trial locations, not the provider’s service territory.
Start is the reported EU start date; latest update is the CTIS publication date; estimated end is the reported global estimate, which may be in the past. Missing dates are shown as “Not reported”. Operational learnings describe the trial as a whole and do not establish the provider’s responsibility.
Clear service synonyms are grouped; otherwise the source label is retained. Service tags show the recorded roles for each trial. This page groups 1 recorded name variant under Biomapas UAB. Legacy brands remain separate unless explicitly matched in the name registry.
View recorded company names
- Biomapas UAB